Medical vs. Endovascular Treatment in Uncomplicated Type B Aortic Dissection

Under much debate, the treatment of uncomplicated type B aortic dissection is still uncertain. Several studies with methodological limitations have shown that endovascular treatment plus optimal medical treatment might be beneficial, compared with medical treatment alone.

Evaluación Hemodinámica de la Insuficiencia Aórtica post TAVR

This meta-analysis sought to define more clearly the treatment strategy in patients with acute and subacute uncomplicated type B aortic dissection. To that end, researchers conducted a systematic review and meta-analysis of observational studies and randomized trials.

The primary endpoints were early mortality and re-intervention, late all-cause and aorta-related mortality, and late re-intervention.


Read also: PASCAL in Tricuspid Regurgitation with Encouraging Results.


Researchers analyzed 6 studies with a total of 14,706 patients; 1066 of them underwent endovascular treatment.

There were no significant differences between endovascular treatment and medical treatment with regards to early mortality (p = 0.46), early re-interventions (p = 0.19), or surgery (p = 1).

Medical treatment was significantly associated with a lower risk of early stroke (p = 0.002) but a higher risk of late all-cause mortality (p < 0.001) and aorta-related mortality (p = 0.001), compared with endovascular treatment.

Conclusion

Given the limited number and, particularly, the limited quality of studies on endovascular treatment vs. medical treatment in patients with acute or subacute uncomplicated type B aortic dissection, a categorical recommendation remains uncertain. Further information is required to understand which dissections and patients would benefit from preventive treatment.

Original title: Endovascular vs. Medical Management for Uncomplicated Acute and Subacute Type B Aortic Dissection: A Meta-analysis.

Reference: Martin Hossack et al. Eur J Vasc Endovasc Surg. Article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

New Carotid PCI All-in-One System

Carotid stenting is equivalent to carotid endarterectomy in terms of major adverse events (death, AMI, and stroke). However, it entails higher risk of minor...

PERFORMANCE II Trial: Safety and Efficacy of the New NeuroGuard Carotid Stent System

The percutaneous treatment of carotid artery disease through stenting (CAS) for the prevention of cerebrovascular disease has proven to be an effective alternative compared...

Trends in the Treatment of Critical Lower Limb Ischemia

Approximately 25% of patients with critical lower limb ischemia (CLLI) face amputation within the first year after diagnosis (according to statistics from the United...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Unplanned Coronary Angiography After TAVR: Incidence, Predictors, and Outcomes

The importance of assessing coronary artery disease in patients undergoing transcatheter aortic valve replacement (TAVR) is well recognized due to the high prevalence of...

Intravascular Lithotripsy in Calcified Coronary Lesions: Success Predictors

Coronary artery calcification (CAC) is increasingly common in patients undergoing percutaneous coronary intervention (PCI). Intravascular lithotripsy (IVL) has been established as an effective tool...

TAVR Unload: TAVR in Moderate Aortic Stenosis and Ventricular Function Deterioration

Aortic Stenosis (AS) significantly contributes to valvulo-arterial impedance in patients with heart failure and reduced ejection fraction (HFrEF), making it a relevant therapeutic target...